LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Geschlossen

39.31 3.8

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

38.18

Max

39.87

Schlüsselkennzahlen
By Trading Economics
Einkommen	-7.4M -81M
EPS	-0.5
Gewinnspanne	-1,582.642
Angestellte	205
EBITDA	-6.8M -79M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+15.04% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	4B 6.2B
Vorheriger Eröffnungskurs	35.51
Vorheriger Schlusskurs	39.31

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

19. Dez. 2025, 17:29 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19. Dez. 2025, 16:47 UTC

Wichtige Markttreiber

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19. Dez. 2025, 16:10 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

20. Dez. 2025, 19:00 UTC

Ergebnisse

Consumer Confidence, Economic Activity Data, and a Short Trading Week for Christmas -- Barrons.com

19. Dez. 2025, 22:33 UTC

Ergebnisse

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19. Dez. 2025, 22:19 UTC

Ergebnisse

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19. Dez. 2025, 21:48 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. Dez. 2025, 21:44 UTC

Ergebnisse

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19. Dez. 2025, 21:38 UTC

Ergebnisse

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19. Dez. 2025, 21:00 UTC

Market Talk

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19. Dez. 2025, 20:23 UTC

Market Talk

Oil Futures End Down Week on Up Note -- Market Talk

19. Dez. 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19. Dez. 2025, 18:38 UTC

Market Talk

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19. Dez. 2025, 18:00 UTC

Market Talk

Ergebnisse

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19. Dez. 2025, 17:41 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19. Dez. 2025, 17:24 UTC

Market Talk

Ergebnisse

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19. Dez. 2025, 17:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

19. Dez. 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

19. Dez. 2025, 16:29 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19. Dez. 2025, 16:20 UTC

Akquisitionen, Fusionen, Übernahmen

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19. Dez. 2025, 16:19 UTC

Akquisitionen, Fusionen, Übernahmen

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19. Dez. 2025, 16:18 UTC

Akquisitionen, Fusionen, Übernahmen

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19. Dez. 2025, 16:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. Dez. 2025, 16:16 UTC

Market Talk

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19. Dez. 2025, 16:05 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. Dez. 2025, 16:04 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. Dez. 2025, 15:37 UTC

Market Talk

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19. Dez. 2025, 15:21 UTC

Market Talk

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19. Dez. 2025, 15:09 UTC

Market Talk

Gold Flat But Set for Weekly Gains -- Market Talk

19. Dez. 2025, 15:09 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

15.04% Vorteil

12-Monats-Prognose

Durchschnitt 45.5 USD 15.04%

Hoch 67 USD

Tief 30 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.